Published in J Bone Miner Metab on June 09, 2010
Rapid skeletal turnover in a radiographic mimic of osteopetrosis. J Bone Miner Res (2014) 2.00
Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation. J Bone Miner Res (2013) 0.84
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. Clin Genitourin Cancer (2014) 0.83
Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid. J Bone Miner Metab (2012) 0.78
The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment. Ital J Pediatr (2014) 0.77
Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK. J Bone Miner Res (2014) 0.76
Effect of zoledronic acid on serum calcium in Paget's disease patients after educational strategies to improve calcium and vitamin D supplementation. Ther Adv Endocrinol Metab (2015) 0.75
Bone resorption: an actor of dental and periodontal development? Front Physiol (2015) 0.75
Polymorphisms of CSF1 and TM7SF4 genes in a case of mild juvenile Paget's disease found using next-generation sequencing. Croat Med J (2015) 0.75
Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr (2003) 4.24
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med (2002) 3.34
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) 3.13
Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res (2007) 1.94
Bisphosphonate-associated adverse events. Hormones (Athens) (2009) 1.36
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet (2002) 1.32
Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med (2005) 1.27
Healing of the bones in juvenile Paget's disease treated by human calcitonin. Br J Radiol (1974) 1.14
Biochemical assessment of Paget's disease of bone. J Bone Miner Res (2006) 0.95
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res (2004) 0.94
Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission. J Bone Miner Res (2001) 0.91
Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy. Bone (2004) 0.91
Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone (2006) 0.86
Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J Bone Miner Metab (2008) 0.85
Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders. Best Pract Res Clin Rheumatol (2008) 0.85
Chronic idiopathic hyperphosphatasia. Report of a case treated with pamidronate and a review of the literature. J Rheumatol (1992) 0.82
Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos Int (2008) 0.82
Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res (1996) 0.79
Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium. Bone (1999) 0.79
Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. J Pediatr Endocrinol Metab (2000) 0.79
Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support Care Cancer (2009) 0.78
Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-kappaB, osteoprotegerin, or sequestosome-1 gene defects. J Clin Endocrinol Metab (2007) 0.77
The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone. Horm Metab Res (2009) 0.76
Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. J Bone Miner Res (1994) 0.75
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 6.05
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica (2007) 2.44
Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol (2008) 2.29
Bilateral ovarian agenesis and the presence of the testis-specific protein 1-Y-linked gene: two new features of Mayer-Rokitansky-Küster-Hauser syndrome. Fertil Steril (2004) 2.00
Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother (2013) 1.98
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica (2006) 1.71
Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol (2004) 1.68
Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis. Thyroid (2010) 1.68
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma (2008) 1.61
Clinical complications following thyroid fine-needle biopsy: a systematic review. Clin Endocrinol (Oxf) (2009) 1.59
Acute transient thyroid swelling following needle biopsy: an update. Hormones (Athens) (2012) 1.59
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol (2006) 1.51
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica (2006) 1.49
Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol (2003) 1.49
Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma (2006) 1.42
Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid (2003) 1.40
Aurora kinases as targets for cancer therapy. Cancer Treat Rev (2007) 1.33
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev (2008) 1.32
The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs (2008) 1.31
Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol (2013) 1.28
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood (2012) 1.27
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer (2006) 1.21
Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res (2009) 1.21
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist (2012) 1.18
Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica (2007) 1.18
Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 1.17
New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol (2004) 1.16
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res (2005) 1.16
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol (2007) 1.15
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood (2012) 1.14
Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol (2008) 1.14
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol (2012) 1.14
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma (2009) 1.11
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer (2009) 1.09
Baker's cysts in knees with chronic osteoarthritic pain: a clinical, ultrasonographic, radiographic and scintigraphic evaluation. Rheumatol Int (2008) 1.09
Thyroid nodules - stepwise diagnosis and management. Hormones (Athens) (2007) 1.08
Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Am J Med Genet A (2004) 1.07
Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol (2008) 1.06
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol (2007) 1.06
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res (2010) 1.06
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer (2011) 1.05
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma (2007) 1.02
Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol (2008) 1.01
Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol (2011) 1.01
Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets (2009) 1.01
Sickle-cell disease and the heart: review of the current literature. Br J Haematol (2012) 1.00
Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism (2012) 1.00
Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs (2012) 0.99
Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. Eur J Haematol (2014) 0.99
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol (2011) 0.99
Regulation of multiple myeloma survival and progression by CD1d. Blood (2008) 0.98
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol (2004) 0.98
A systematic review of cases reporting needle tract seeding following thyroid fine needle biopsy. World J Surg (2010) 0.97
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leuk Lymphoma (2011) 0.96
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol (2010) 0.96
Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol (2009) 0.95
Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol (2011) 0.95
The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer (2013) 0.95
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol (2013) 0.95
Pathogenesis and management of myeloma bone disease. Expert Rev Hematol (2009) 0.94
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res (2008) 0.94
Systematic review of cases reporting blood extravasation-related complications after thyroid fine-needle biopsy. J Otolaryngol Head Neck Surg (2010) 0.93
Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase. J Cancer Res Clin Oncol (2008) 0.93
Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. Aging Cell (2013) 0.93
High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem (2008) 0.92
Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol (2009) 0.92
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. Transl Res (2010) 0.92
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma (2010) 0.91
Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev (2012) 0.91
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol (2011) 0.91
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. Am J Hematol (2013) 0.91
Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev (2008) 0.91
Tobacco smoking and risk of multiple myeloma: a meta-analysis of 40 observational studies. Int J Cancer (2012) 0.90
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leuk Lymphoma (2014) 0.90
Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. Haematologia (Budap) (2002) 0.90
Alterations in serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review. Thyroid (2010) 0.90
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol (2014) 0.90
The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol (Oxf) (2009) 0.90
Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones (Athens) (2011) 0.90
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism (2012) 0.89
Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol (2014) 0.89
Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur J Immunol (2010) 0.89
Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells. Am J Hematol (2011) 0.89
Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. Br J Haematol (2009) 0.89
Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene). J Clin Endocrinol Metab (2014) 0.89